
About 10–15% of all instances of breast cancer are triple-negative breast cancer (TNBC), an uncommon yet aggressive and rapidly spreading cancer that lacks three typical receptors found in most breast cancers: estrogen receptors (ER), progesterone receptors (PR), and the HER2 protein. Globally, TNBC is the most common cause of death for females and the most aggressive type of metastatic cancer.
Timely treatment of Triple-negative breast Cancer is crucial for many possible reasons :
Traditional risk factors for all types of breast cancer, including lifestyle and environmental factors, also apply to triple-negative breast cancer. The exact causes of TNBC are not fully recognised, but several factors are involved in its development:
Risk Factors
High-resolution imaging, genetic analysis, and individualized therapy regimens have helped Turkey make tremendous strides in the diagnosis and treatment of triple-negative breast cancer (TNBC). In clinical trials conducted at several Turkish oncology facilities, immunotherapy—specifically, pembrolizumab in combination with chemotherapy—has demonstrated encouraging outcomes. In order to provide patients with access to innovative therapies like antibody-drug conjugates and customized vaccinations, Turkish hospitals actively take part in international clinical trials.
Triple-negative breast cancer (TNBC) cannot be prevented, although there are lifestyle behaviours that can lower the risk. Here are some tips-
Medical professionals and researchers are still looking at novel approaches to treating TNBC. Recent clinical studies are evaluating novel drug combinations and new approaches to current therapies. The following are a few current treatments:
Chemotherapy: Healthcare providers might combine chemotherapy and surgery to treat early-stage triple-negative breast cancer. Which might be given before the surgery to shrink the tumour size and also post-surgery to kill any remaining cancer cells and reduce the risk of recurrence.
Cost Start From USD 7420 - USD 30000Explore Options
Immunotherapy: Healthcare Providers may combine immunotherapy and chemotherapy to shrink the size of tumors before surgery.
Cost Start From USD 7420 - USD 42500Explore Options
Targeted Therapy: Treatments that target malignant cells may be combined with immunotherapy and chemotherapy. For instance, doctors might employ PARP inhibitors as a targeted therapy. Poly ADP ribose polymerase, or PARP for short, is a cellular enzyme that fixes damage to DNA.
Cost Start From USD 7500 - USD 12000Explore Options
Lumpectomy: It is the removal of a small margin of the surrounding tissue of the breast. It is also known as breast-conserving surgery. A lumpectomy may be followed by radiation treatments to treat any residual cancer cells.
Mastectomy: It is the removal of the entire breast. Mastectomy is a treatment for patients with multiple, very aggressive, or large invasive ductal tumours in most advanced cases.
Cost Start From USD 6000 - USD 75000Explore Options
Clinical Evaluation
Imaging Studies
Biopsy
Laboratory Tests
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services to support patients through Teleconsulations and online therapy sessions.
Depending on the circumstances, your doctor might recommend medication to help manage your symptoms and complement the course of treatment.









Istanbul, Turkey
Medicana Camlica Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:

Istanbul, Turkey
Architecture of the Hospital designed as per the comfort of patients-

Istanbul, Turkey
Acibadem Kadikoy Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
A worse prognosis is frequently associated with triple-negative breast cancer (TNBC), a more aggressive kind of the disease that develops and spreads quickly. Treatment options are limited because TNBC cannot be treated with hormonal or targeted therapy due to its lack of estrogen, progesterone, and HER2 receptors. Because of its aggressive character, early detection and prompt treatments are crucial for better results.
Within weeks to months, triple-negative breast cancer (TNBC) frequently grows and spreads. Because of its aggressive nature, early detection and timely treatment are essential.
The adverse effects vary from therapy to treatment. Furthermore, how each person responds to these side effects may vary. Inquire about the adverse impact of a particular treatment from your doctor. They will outline how they will assist you in managing them and what you may do to benefit yourself.
Recent advancements in the discovery of novel therapies, including immunotherapy and PARP inhibitors, have improved the prognosis for TNBC. Medical researchers are using existing treatments in novel ways. The prognosis for triple-negative breast cancer is better the earlier medical professionals identify it, as is the case with most cancers.
The stage at which triple-negative breast cancer (TNBC) is diagnosed affects the survival rate. About 91% of people with localised TNBC, 66% of people with regional TNBC, and 12% of people with distant TNBC will survive for five years. All stages together have a 5-year survival rate of about 77%2. Improving outcomes requires early detection and timely treatment.
Yes, triple-negative breast cancer (TNBC) can cause irreparable harm, particularly if the disease is not identified and treated quickly. TNBC is an aggressive type of breast cancer that can cause more serious and reversible harm by swiftly spreading to lymph nodes and other body parts. Early detection and timely treatment are essential to avoid irreparable harm and increase the likelihood of positive results.
One can go home 1-2 days after the Lumpectomy surgery, and it takes 5-10 days to recover and fully regain normal activities. Similarly, 1-2 days of hospital stay in Mastectomy and 3-4 weeks of full recovery to normal activities.
Yes, Turkey provides cutting-edge diagnostic techniques for Triple-Negative Breast Cancer (TNBC), such as molecular profiling, MRI, PET-CT, and digital mammography. Top hospitals offer modern imaging and biopsy methods for accurate diagnosis.
Turkey is a cost-effective choice for those seeking treatment because it provides top-notch medical care at affordable costs when compared to several Western nations.
Yes, Turkey's healthcare system accepts patients from abroad and provides excellent TNBC treatments at many clinics and hospitals.
Yes, many Turkish hospitals offer in-person and online consultations to foreign patients who want a second opinion.
Yes, immunotherapy is frequently used in conjunction with chemotherapy to improve the prognosis of patients with TNBC.